The size of the medium-sized pharmaceutical market reached 1000.5 billion dollars

New York, July 15. 08, 2022 (GLOBE NEWSWIRE) — The Insight Partners has published the latest research study on “Medium Pharmaceutical Market Forecast to 2028 – Impact of COVID-19 and Global Analysis – by Type, Drug Development Type, Formulation, Therapeutic Class, and Geography”, the report highlights the prevailing trends in the market and the factors driving its growth. The growth of the medium-sized pharmaceutical market is attributed to the increasing prevalence of chronic diseases, the increase in the elderly population and increasing number of product launches and approvals, however, the fierce competition among market players and unfavorable reimbursement scenarios are hampering the growth of the market.

Download PDF Brochure on Mid-Size Pharmaceutical Market Size – Impact of COVID-19 and Global Analysis with Strategic Developments at:

Scope and Strategic Outlook of the Mid-Size Pharmaceutical Market Report:

Report cover Details
Market size Value in US$651.3 billion in 2022
Market Size Value by 1000.5 billion dollars by 2028
Rate of growth CAGR of 6.4% from 2022 to 2028
Forecast period 2022-2028
Year of reference 2022
Number of pages 203
Number of tables 111
Number of graphs and figures 79
Historical data available Yes
Segments Covered Type, type of drug development, formulation and therapeutic class
Regional scope North America; Europe; Asia Pacific; Latin America; AEM
Country scope United States, United Kingdom, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends

Mid-Size Pharmaceutical Market: Competitive Landscape and Key Developments

DAIICHI SANKYO COMPANY LIMITED; Eisai Co., Ltd. ; Regeneron Pharmaceuticals, Inc; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Ltd; Alexion Pharmaceuticals, Inc.; Mallinckrodt; Endo Pharmaceuticals Inc.; Servier Laboratories; and UCB SA are among the leaders in the medium-sized pharmaceutical market. The market is expected to flourish in the coming years due to the development of new and innovative products by market players.

Pre-purchase inquiry:

  • In May 2022, Takeda and Daiichi Sankyo announced the research project’s collaboration with Tohoku University and MICIN, a digital health and telemedicine company. The collaboration aims to develop a wearable device that will track lifestyle habits. Takeda and Daiichi Sankyo hope the research project can lead to new discoveries of new medical technologies and new drugs.
  • In April 2022, Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. announced a definitive agreement for Regeneron to acquire Checkmate. The total value of Checkmate shares is estimated to be approximately US$250 million in the proposed acquisition.

North America is the largest market for mid-sized pharmaceuticals, and the United States holds the largest regional market share, followed by Canada. The growth of the mid-sized pharmaceutical market in the United States is attributed to the increase in the elderly population, the growth of chronic diseases among the elderly population and the increase in government expenditure in the healthcare sector. According to the US Census Bureau, in the United States, people aged 65 and over are expected to double from 52 million in 2018 to around 95 million by 2060, and people aged 65 and over will increase by 16% to 23% in 2018. to 2060.

Have a question? Speak to the Research Analyst:

Most adults (>60%) suffer from two or more chronic conditions. According to the Centers for Disease Control and Prevention (CDC), in 2020 nearly 6 in 10 people in the United States had at least one chronic condition, and 4 in 10 people had two or more chronic conditions. Additionally, chronic conditions, such as dementia, heart disease, type 2 diabetes, arthritis, and cancer, are associated with aging. They are significant causes of illness, disability, death, and increased health care costs in the United States. Thus, the growing prevalence of chronic diseases will generate the need for affordable long-term therapies, thereby driving the growth of the medium-sized pharmaceutical market.

Rise in Product Approvals and Launches Fueling Growth of Mid-Size Pharma Market

The medium-sized pharmaceutical market is characterized by the presence of various market players. To increase their market share, market players are adopting various strategies such as product launches, regional expansion, and technological advancements. Mid-sized pharmaceutical companies are more involved in continuous innovation and technological advancements, which leads to increased acceptance by industry players. Major players are investing in R&D to develop advanced technologies and generate more revenue.

Take advantage of lucrative discounts on the “Medium-Sized Pharmaceutical Market” research study:

Some recent developments related to the medium-sized pharmaceutical industry are mentioned below:

In May 2022, Sun Pharmaceutical Industries Ltd., including its subsidiaries and associated companies, announced that it had received final approval from the US FDA for its abbreviated new drug application (ANDA) for generic mesalamine extended-release capsules, 500mg. The generic product approval was based on Pentasa extended-release capsules, 500 mg as the reference product.

In February 2022, UCB SA received approval to treat seizures associated with Lennox-Gastaut Syndrome (LGS), a rare form of childhood epilepsy. The drug, branded Fintepla, is approved in the United States to treat another form of childhood epilepsy, Davet’s syndrome (DS), in patients aged two years and older. Developed by Zogenix, Fintepla is only available through a restricted drug distribution program in the United States

Active participation of market players in product innovation and development coupled with increase in product approvals is fueling the growth of the mid-sized pharmaceutical market.

Mid-Size Pharmaceutical Market: Segmental Overview

Based on type, the mid-sized pharmaceutical market is divided into prescription and over-the-counter drugs. The over-the-counter segment held a larger market share in 2022. The segment is expected to register a higher CAGR during the period 2022-2028.

In terms of the type of drug development, the mid-sized pharmaceutical market is divided into in-house and outsourced. The outsourcing segment held a larger market share in 2022 and is expected to continue to be a larger shareholder by 2028.

Based on formulation, the medium-sized pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. In 2022, tablets and capsules segment held the largest market share. The segment is expected to register the highest CAGR between 2022 and 2028.

On the basis of therapeutic class, the mid-sized pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer and other conditions. In 2022, the diabetes segment held the largest market share. However, the cancer segment is expected to register the highest CAGR between 2022 and 2028.

Buy a premium copy of the Midsize Pharmaceutical Market Growth Report (2022-2028) directly at:

Cycle through adjacent reports:

Radiopharmaceuticals Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Product Type (Technetium-99m, Thallium-201, Gallium-67, Iodine-131, copper-64 and others), Application (oncology, cardiology, neurology and others) and end user (hospitals, imaging centers, academic and research centers and others)

Over-the-Counter Drugs Market Forecast to 2028 – Impact of Covid-19 and Global Analysis – By Product Type (Dermatology Products, Weight Loss or Diet Products, Sleeping Pills, Gastrointestinal Products, Cough Products, cold and flu, painkillers, vitamins, minerals and supplements (VMS), ophthalmic products, other types of products); Distribution channel (hospital pharmacies, retail pharmacies, online pharmacy, other distribution channels) and geography

Over-the-Counter Analgesics Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Drug Type (Acetaminophen and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)); Route of administration (oral, topical and parenteral); Distribution channel (hospital pharmacies, retail pharmacies, e-commerce and home care) and geography

Nanopharmaceuticals Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Carrier Type (Nanocrystals, Proteins, Liposomes, Polymers, Inorganics and Other Carriers); Application (Anti-infectious, anti-inflammatory, cardiovascular, oncological, neurological and other applications); End user (hospital pharmacies, retail pharmacies and other pharmacies)

Prescription Drugs Market Forecast to 2028 – Impact of COVID-19 and Global Analysis by Product Type (Generic, Orphan, Other); Therapy (oncology, antidiabetics, vaccines, sensory organs, immunosuppressants, anticoagulants, others); Distribution channel (hospital pharmacies, online pharmacies, retail pharmacies and pharmacies) and geography

About Us:
The Insight Partners is an industry unique research provider of actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as Semiconductors and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Health IT, Manufacturing and Construction, Medical Devices , technology, media and telecommunications, chemicals and materials.

Contact us:
If you have any questions about this report or would like further information, please contact us:

Contact person: Sameer Joshi
Email: [email protected]
Phone: +1-646-491-9876
Press release:

Back To Top